Filing Details

Accession Number:
0001567619-21-004615
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-22 18:00:03
Reporting Period:
2021-02-18
Accepted Time:
2021-02-22 18:00:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184149 W Jonathan Ayers One Idexx Drive
Westbrook ME 04092
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-05 8,000 $0.00 652,737 No 5 G Direct
Common Stock Acquisiton 2021-02-18 1,000 $79.54 653,737 No 4 M Direct
Common Stock Disposition 2021-02-18 1,000 $555.56 652,737 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Acquisiton 2021-02-18 1,000 $0.00 1,000 $79.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
147,632 2025-02-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,000 Indirect by Ayers Family Trust
Footnotes
  1. Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  2. Not applicable.